

Allianz

China Equity

Monthly commentary

- The Fund aims at long-term capital growth by investing in equity markets in the People's Republic of China ("PRC"), Hong Kong and Macau in accordance with environmental and social characteristics. The Fund aims to achieve an outperformance (i.e. achieve a higher Environment, Social and Governance ("ESG") score) of the Fund's weighted average ESG score compared to weighted average ESG score of Fund's benchmark index by the adoption of the ESG Score Strategy. The Fund does not constitute as an ESG fund pursuant to the SFC's circular issued on 29 June 2021.
- The Fund is exposed to significant risks of investment/general market, country and region, emerging market, company-specific, currency (such as exchange controls, in particular RMB), and the adverse impact on RMB share classes due to currency depreciation.
- The Fund may invest in the China A-Shares market directly via the Stock Connect or other foreign access regimes and/or other permitted means and/or indirectly through all eligible instruments and thus is subject to the associated risks (including quota limitation, change in rule and regulations, repatriation of the Fund's monies, trade restrictions, China market volatility and uncertainty, potential clearing and/or settlement difficulties, change in economic, social and political policy in PRC and Mainland China tax risks).
- The Fund is exposed to risks relating to ESG Score Strategy investment (such as foregoing opportunities to buy certain securities when it might otherwise be advantageous to do so, selling securities when it might be disadvantageous to do so, and/or reducing risk diversifications compared to broadly based funds) which may result in the Fund being more volatile and have adverse impact on the performance of the Fund and consequently adversely affect an investor's investment in the Fund.
- The Fund may invest in financial derivative instruments ("FDI") which may expose to higher leverage, counterparty, liquidity, valuation, volatility, market and over the counter transaction risks. The Fund's net derivative exposure may be up to 50% of the Fund's net asset value.
- This investment may involve risks that could result in loss of part or entire amount of investors' investment.
- In making investment decisions, investors should not rely solely on this material.

Note: Dividend payments may, at the sole discretion of the Investment Manager, be made out of the Fund's capital or effectively out of the Fund's capital which represents a return or withdrawal of part of the amount investors originally invested and/or capital gains attributable to the original investment. This may result in an immediate decrease in the NAV per share and the capital of the Fund available for investment in the future and capital growth may be reduced, in particular for hedged share classes for which the distribution amount and NAV of any hedged share classes (HSC) may be adversely affected by differences in the interests rates of the reference currency of the HSC and the base currency of the Fund.

What Happened in October

The Fund lagged the benchmark MSCI China 10/40 Index in October. Stock selection in the healthcare and consumer discretionary sectors were the main detractors.

At a stock level, a detractor last month was a biotech company focused on autoimmune and oncology-related drug development. The share price pullback was in line with broader profit-taking in the sector. In our view, the company has a number of potential future catalysts given its drug development pipeline. We also expect further out-licensing deals as global pharmaceutical companies look to replenish their product portfolios in the face of looming patent cliffs.

Conversely, a key contributor was a company that is a market leader in tap changers, a critical component in power transformers that regulate voltage for stable electricity transmission. Longer term, we expect a robust power grid capex cycle in China, with upside from artificial intelligence (AI)-driven data center demand as well as the integration of renewable energy supply. This should support demand for the company's products. Added to this, overseas orders have also been strong, driven by market share gains and global expansion.

Outlook and Strategy

October was a period of consolidation for China equities, not a surprise after the rapid pace of the rally in recent months. It was also a rotational market with profit-taking in technology and AI-related areas, and previous laggard sectors such as energy and financials being more resilient. In this environment, China A shares outperformed offshore equities during the month. Year to date, both China A and China H shares have returned more than 25% in USD terms.

The main talking points during the month were geopolitics and China's latest five-year plan.

In terms of US-China relations, the cycle of tension, escalation and truce appears to be a new normal. Whether this latest truce lasts a full year, as announced, is questionable. Nonetheless, for the time being the most recent agreement should at least provide a degree of relief. Similar to "Liberation Day," cooler heads have prevailed, which was to be expected given that both the US and China had a lot to lose from some of the more extreme measures being threatened.

Overall, both sides look to be buying time while making efforts to reduce their dependence on one another. From a US perspective, the focus has been finding alternative sources of rare earth supply. In our view, this is likely to be challenging. China's grip is strongest on the most important and scarcest metals, 'heavy' rare earths, which are needed to produce permanent magnets essential for much high-tech equipment. China and Myanmar together account for 98% of global heavy rare earth supply, and essentially all processing of these ores currently occurs in China.

To give some sense of scale, China has an estimated 120,000 people working in the rare earths industry, the result of making it a high strategic priority over a sustained period. Any path to breaking Chinese dominance would appear to be many years away and, as such, China's geopolitical advantage in this area is likely to be long lasting.

From China's perspective, a key vulnerability is its reliance on Western high-spec technology, especially in the semiconductor supply chain. Although it has significantly ramped up self-sufficiency in recent years, important industries such as more advanced electric vehicles still rely primarily on imported semiconductors.

This explains the context of China's latest five-year plan, which underscored the determination to build a more self-reliant technology ecosystem. As well as a focus on achieving broader technological self-sufficiency, there were also references to emerging high-tech industries over the next decade that are potentially at risk from reliance on Western supply chains. These include areas such as quantum technology, biological manufacturing, hydrogen energy and nuclear fusion energy, and 6G mobile telecommunications.

Perhaps the biggest surprise out of the plenum which approved the five-year plan policy framework was a statement that this year's annual GDP growth target must be accomplished, and a call for more economic policy support. This was unexpected as the plenum is typically dedicated to more strategic issues. It likely reflects concern about slowing economic momentum and reinforces our expectations for incremental policy stimulus in Q4 2025.

This ongoing more supportive policy backdrop, combined with the technology narrative and strong domestic liquidity, leads us to remain optimistic on the China equity outlook.

During the month, we took profits in a number of stocks which have seen strong share price performance year to date. As a result, the technology sector weighting was reduced close to a neutral position compared to benchmark. We reallocated some of the funds to the financial sector which has lagged recently and where the high dividend yields should provide valuation support.

The portfolio is positioned with relatively close to benchmark sector allocations so that stock selection is the key relative performance driver. At month end, the largest sector overweight is industrials, while the largest underweight is consumer staples.

Connect with Us

hk.allianzgi.com

+852 2238 8000

Search more



Like us on Facebook 安聯投資 – 香港



Connect on LinkedIn Allianz Global Investors



Subscribe to YouTube channel 安聯投資

Source: Bloomberg, Allianz Global Investors, as of 31 October 2025 unless otherwise stated.

*The information above is provided for the purpose to demonstrate the Fund's investment strategy only, it should not be considered a recommendation nor investment advice to buy or sell any shares of securities. There is no assurance that any securities discussed herein will remain in the Fund at the time you receive this document.

Any securities mentioned (above) is for illustrative purposes only. It should not be considered as an investment advice, or a recommendation to buy or sell any particular security or strategy.

Information herein is based on sources we believe to be accurate and reliable as at the date it was made. We reserve the right to revise any information herein at any time without notice. No offer or solicitation to buy or sell securities and no investment advice or recommendation is made herein. In making investment decisions, investors should not rely solely on this material but should seek independent professional advice.

Investment involves risks, in particular, risks associated with investment in emerging and less developed markets. Past performance is not indicative of future performance. Investors should read the offering documents for further details, including the risk factors, before investing. This material and website have not been reviewed by the Securities and Futures Commission of Hong Kong. Issued by Allianz Global Investors Asia Pacific Limited.

Allianz Global Investors Asia Pacific Limited (32/F, Two Pacific Place, 88 Queensway, Admiralty, Hong Kong) is the Hong Kong Representative and is regulated by the Securities and Futures Commission of Hong Kong (54/F, One Island East, 18 Westlands Road, Quarry Bay, Hong Kong).